Prevention of stroke in patients with atrial fibrillation

Talal Moukabary, Gerald V. Naccarelli

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The presence of atrial fibrillation (AF) increases the risk of stroke, especially in patients with risk factors as outlined by the CHADS 2 and CHA2DS 2-VASc scoring systems. Although warfarin can reduce stroke rates by over 65%, only 55% of patients, in the USA, who should be on warfarin for AF and stroke prevention are taking the drug due to the need of INR monitoring, difficulties in maintaining a therapeutic INR in the therapeutic range and dietary and drug interactions. Dabigatran, an oral direct thrombin inhibitor and rivaroxaban and apixaban, factor Xa inhibitors, have demonstrated efficacy in reducing stroke in large clinical trials. These novel anticoagulants will change the therapeutic landscape since patients will be able to prevent stroke with a lower risk of intracranial hemorrhage and without the need for INR monitoring and less drug-dietary interactions.

Original languageEnglish (US)
JournalJournal of Atrial Fibrillation
Volume2
Issue number8
StatePublished - Dec 1 2011

Fingerprint

Atrial Fibrillation
Stroke
International Normalized Ratio
Warfarin
Drug Interactions
Antithrombins
Intracranial Hemorrhages
Anticoagulants
Therapeutics
Clinical Trials
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{2da1404733fa430bae0cb73f7abb77a1,
title = "Prevention of stroke in patients with atrial fibrillation",
abstract = "The presence of atrial fibrillation (AF) increases the risk of stroke, especially in patients with risk factors as outlined by the CHADS 2 and CHA2DS 2-VASc scoring systems. Although warfarin can reduce stroke rates by over 65{\%}, only 55{\%} of patients, in the USA, who should be on warfarin for AF and stroke prevention are taking the drug due to the need of INR monitoring, difficulties in maintaining a therapeutic INR in the therapeutic range and dietary and drug interactions. Dabigatran, an oral direct thrombin inhibitor and rivaroxaban and apixaban, factor Xa inhibitors, have demonstrated efficacy in reducing stroke in large clinical trials. These novel anticoagulants will change the therapeutic landscape since patients will be able to prevent stroke with a lower risk of intracranial hemorrhage and without the need for INR monitoring and less drug-dietary interactions.",
author = "Talal Moukabary and Naccarelli, {Gerald V.}",
year = "2011",
month = "12",
day = "1",
language = "English (US)",
volume = "2",
journal = "Journal of Atrial Fibrillation",
issn = "1941-6911",
publisher = "Cardiofront, Inc.",
number = "8",

}

Prevention of stroke in patients with atrial fibrillation. / Moukabary, Talal; Naccarelli, Gerald V.

In: Journal of Atrial Fibrillation, Vol. 2, No. 8, 01.12.2011.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Prevention of stroke in patients with atrial fibrillation

AU - Moukabary, Talal

AU - Naccarelli, Gerald V.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - The presence of atrial fibrillation (AF) increases the risk of stroke, especially in patients with risk factors as outlined by the CHADS 2 and CHA2DS 2-VASc scoring systems. Although warfarin can reduce stroke rates by over 65%, only 55% of patients, in the USA, who should be on warfarin for AF and stroke prevention are taking the drug due to the need of INR monitoring, difficulties in maintaining a therapeutic INR in the therapeutic range and dietary and drug interactions. Dabigatran, an oral direct thrombin inhibitor and rivaroxaban and apixaban, factor Xa inhibitors, have demonstrated efficacy in reducing stroke in large clinical trials. These novel anticoagulants will change the therapeutic landscape since patients will be able to prevent stroke with a lower risk of intracranial hemorrhage and without the need for INR monitoring and less drug-dietary interactions.

AB - The presence of atrial fibrillation (AF) increases the risk of stroke, especially in patients with risk factors as outlined by the CHADS 2 and CHA2DS 2-VASc scoring systems. Although warfarin can reduce stroke rates by over 65%, only 55% of patients, in the USA, who should be on warfarin for AF and stroke prevention are taking the drug due to the need of INR monitoring, difficulties in maintaining a therapeutic INR in the therapeutic range and dietary and drug interactions. Dabigatran, an oral direct thrombin inhibitor and rivaroxaban and apixaban, factor Xa inhibitors, have demonstrated efficacy in reducing stroke in large clinical trials. These novel anticoagulants will change the therapeutic landscape since patients will be able to prevent stroke with a lower risk of intracranial hemorrhage and without the need for INR monitoring and less drug-dietary interactions.

UR - http://www.scopus.com/inward/record.url?scp=84455171278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84455171278&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84455171278

VL - 2

JO - Journal of Atrial Fibrillation

JF - Journal of Atrial Fibrillation

SN - 1941-6911

IS - 8

ER -